Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Net Income towards Common Stockholders: 2020-2025

Historic Net Income towards Common Stockholders for Fulcrum Therapeutics (FULC) over the last 5 years, with Sep 2025 value amounting to -$19.6 million.

  • Fulcrum Therapeutics' Net Income towards Common Stockholders rose 9.68% to -$19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.5 million, marking a year-over-year increase of 24.63%. This contributed to the annual value of -$9.7 million for FY2024, which is 90.01% up from last year.
  • Fulcrum Therapeutics' Net Income towards Common Stockholders amounted to -$19.6 million in Q3 2025, which was down 10.99% from -$17.7 million recorded in Q2 2025.
  • Fulcrum Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$16.6 million during Q4 2024, with a 5-year trough of -$34.1 million in Q2 2022.
  • For the 3-year period, Fulcrum Therapeutics' Net Income towards Common Stockholders averaged around -$22.8 million, with its median value being -$24.4 million (2023).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 73.40% in 2022, then skyrocketed by 34.29% in 2025.
  • Quarterly analysis of 5 years shows Fulcrum Therapeutics' Net Income towards Common Stockholders stood at -$23.5 million in 2021, then fell by 11.29% to -$26.1 million in 2022, then increased by 5.28% to -$24.8 million in 2023, then surged by 33.07% to -$16.6 million in 2024, then grew by 9.68% to -$19.6 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$19.6 million for Q3 2025, versus -$17.7 million for Q2 2025 and -$16.6 million for Q4 2024.